ArticleDiscover oncology2025
Leveraging machine learning models to evaluate immune infiltration in the ovarian cancer microenvironment: a single-cell analysis approach.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing prussian blue nanoparticle-mediated photothermal therapy through machine learning and multiomics integration.Nanomedicine (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of ovarian cancer is closely related to the degree of immune cell infiltration within the tumor microenvironment. However, current methods for assessing immune infiltration have certain subjective limitations. This study aimed to establish an objective assessment model based on machine learning and single-cell RNA sequencing data to provide a basis for the individualized immunotherapy of ovarian cancer.
methodsThis study integrated gene expression data from multiple public databases for ovarian cancer, including different histological subtypes and immune infiltration levels. We utilized single-cell RNA sequencing data to characterize immune cell populations with unprecedented resolution. After correcting for batch effects, we constructed machine learning models based on RandomForest and SVM to predict the immune infiltration status of samples at the single-cell level. The models were evaluated and optimized using cross-validation methods.
resultsOur machine learning models demonstrated high accuracy and robustness in predicting the immune infiltration status of ovarian cancer. The RandomForest model achieved an AUC of 0.88 on an independent test set, outperforming traditional immune scoring indices. Single-cell analysis revealed distinct immune cell subpopulations and their spatial distribution within tumors. The models also identified key gene features associated with immune infiltration at cellular resolution, providing clues for further understanding the immune microenvironment of ovarian cancer.
conclusionThe machine learning-based approach for evaluating immune infiltration in ovarian cancer at the single-cell level can rapidly and objectively predict the immune status, and discover potential biomarkers and therapeutic targets. This method provides a new strategy and tool for achieving individualized immunotherapy for ovarian cancer. Clinical trial declaration: This research is not a clinical trial and is exempt from clinical trial registration requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.